#1 Clinical Trials Search in Europe

Study on the Use of 18F-PSMA-1007, Piflufolastat (18F), and Gozetotide for Detecting Pelvic Lymph Node Invasion in Newly Diagnosed Prostate Cancer Patients

3 1 1 1

What is this study about?

This clinical trial is focused on evaluating the effectiveness of a special imaging technique called Prostate-Specific Membrane Antigen Positron Emission Computer Tomography (PSMA PET/CT) in detecting the spread of Prostate Cancer to the pelvic lymph nodes. The study aims to determine if using PSMA PET/CT can help reduce the number of surgical procedures called extended pelvic lymph node dissections (ePLND) that are currently performed on patients with newly diagnosed prostate cancer. The goal is to see if this approach can lower healthcare costs and reduce the burden on patients while maintaining similar outcomes in terms of disease progression.

The study involves three different treatments: 18F-PSMA-1007, PIFLUFOLASTAT (18F), and Locametz 25 micrograms kit for radiopharmaceutical preparation. These are solutions that are injected into the body to help highlight cancer cells during the PSMA PET/CT scan. The trial will compare the results of using these imaging agents with the current standard practice, which involves performing ePLND based on a calculated risk of cancer spread. The study will monitor various outcomes, including the rate of cancer returning after surgery and any complications related to the procedures.

Participants in the study will undergo PSMA PET/CT scans and may receive one of the imaging agents through an intravenous injection. The trial will track the number of surgical procedures performed, the costs associated with these interventions, and any complications that arise. The study will also assess the number of lymph nodes removed during surgery and whether additional PSMA PET/CT scans are needed. The trial is expected to continue until June 2030, with the aim of providing valuable insights into the cost-effectiveness and patient impact of using PSMA PET/CT in the management of prostate cancer.

1 initial assessment

The study begins with an initial assessment to confirm eligibility. This includes verifying age, diagnosis of prostate cancer, and suitability for specific procedures.

Eligibility criteria include being 18 years or older, having a biopsy-proven adenocarcinoma of the prostate, and being suitable for robot-assisted extended pelvic lymph node dissection (ePLND) combined with robot-assisted radical prostatectomy (RARP).

2 informed consent

Participants must provide written informed consent after understanding the potential benefits and burdens of the study.

3 psma pet/ct scan

A PSMA PET/CT scan is performed to detect pelvic lymph node invasion. This scan uses a special imaging technique to help visualize prostate cancer spread.

The scan involves the use of a radiopharmaceutical solution, such as 18F-PSMA-1007, administered through an intravenous injection.

4 surgical procedure

Based on the results of the PSMA PET/CT scan, a decision is made regarding the necessity of performing an extended pelvic lymph node dissection (ePLND) during the robot-assisted radical prostatectomy (RARP).

The goal is to reduce unnecessary surgical procedures and associated complications.

5 post-surgery follow-up

After surgery, follow-up assessments are conducted to monitor recovery and check for any surgical complications within six months.

Biochemical recurrence is evaluated by measuring prostate-specific antigen (PSA) levels, with a focus on detecting any increase above 0.2 ng/ml within two years post-surgery.

6 evaluation of outcomes

The study evaluates the cost-effectiveness of using PSMA PET/CT as a selection tool for ePLND, comparing it to standard practices.

Outcomes include the total number of ePLNDs and PSMA PET/CTs performed, healthcare costs, and the necessity for a second PSMA PET/CT.

Who Can Join the Study?

  • Must be at least 18 years old.
  • Must have a confirmed diagnosis of prostate cancer through a biopsy. A biopsy is a procedure where a small sample of tissue is taken from the body to be examined.
  • Must need a procedure called extended pelvic lymph node dissection (ePLND) along with robot-assisted radical prostatectomy (RARP). ePLND is a surgery to remove lymph nodes in the pelvic area, and RARP is a type of surgery to remove the prostate using robotic assistance.
  • Must be suitable for the combined robot-assisted ePLND and RARP procedures.
  • Must be mentally capable of understanding the benefits and potential challenges of participating in the study.
  • Must provide written informed consent, which means agreeing in writing to participate in the study after being informed about it.

Who Cannot Join the Study?

  • Only male patients can participate. Female patients are not eligible.
  • Patients who are considered part of a vulnerable population cannot participate. This means people who might need extra protection or care, like those with certain disabilities or those who cannot make decisions for themselves.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Zuyderland Medisch Centrum Stichting Geleen The Netherlands
Frisius Heerenveen The Netherlands

Other Sites

Site Name City Country Status
Isala Klinieken Stichting Zwolle The Netherlands
Jeroen Bosch Ziekenhuis Stichting s-Hertogenbosch The Netherlands
Canisius Wilhelmina Ziekenhuis Nijmegen The Netherlands
Amphia Hospital Breda The Netherlands
Ziekenhuisgroep Twente Stichting Almelo The Netherlands
Maxima Medisch Centrum Veldhoven The Netherlands
Maasstad Ziekenhuis Stichting Rotterdam The Netherlands
Catharina Ziekenhuis Stichting Eindhoven The Netherlands
St. Antonius Ziekenhuis Nieuwegein The Netherlands
Meander Medical Center Amersfoort The Netherlands
Reinier de Graaf Groep Delft The Netherlands
Bravis Ziekenhuis Roosendaal The Netherlands
Netherlands Cancer Institute Amsterdam The Netherlands
Rjuyshgju Zopmldihpr Scdqhysiz Arnhem The Netherlands
Awkoawusl Uhx Amsterdam The Netherlands

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
The Netherlands The Netherlands
Not recruiting
20.08.2021

Trial locations

Investigated drugs:

PSMA PET/CT is an imaging technique used to detect prostate cancer spread to the pelvic lymph nodes. It helps doctors decide if a surgical procedure called extended pelvic lymph node dissection (ePLND) is necessary. This method aims to reduce the number of unnecessary surgeries, lower healthcare costs, and decrease the risk of complications for patients, while maintaining effective disease management.

Investigated diseases:

Prostate Cancer – Prostate cancer is a disease where cells in the prostate gland grow uncontrollably. The prostate is a small gland in men that produces seminal fluid. As the disease progresses, it may spread to nearby tissues or other parts of the body. Early stages often show no symptoms, but advanced stages can lead to difficulties in urination, blood in urine, or pelvic discomfort. The progression can vary, with some cases growing slowly and others more aggressively. Monitoring and regular check-ups are crucial to understanding its development.

Trial ID:
2024-518171-59-00
Protocol code:
NL76042.091.21
Trial Phase:
Human Pharmacology (Phase I) – Other

Other Trials to Consider

  • Study on the Use of [18F]PSMA-1007 PET/CT Imaging for Detecting Prostate Cancer in Patients with Newly Diagnosed High-Risk or Very-High-Risk Conditions

    Recruiting

    3 1 1 1
    Investigated drugs:
    France Germany Italy The Netherlands Spain

  • A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

    Recruiting

    3 1 1
    Investigated drugs:
    Austria Belgium Finland France Germany Hungary +5